Lava Therapeutics
Lava Therapeutics is a biotechnology company based in the Netherlands that is developing innovative therapies for cancer. The company was founded in 2016 by Dr. Hans van der Vliet, a leading expert in gamma delta T cell biology and immunotherapy. Lava Therapeutics reported revenue of US$19.4 million for FY 2022
Lava Therapeutics is on a mission to transform cancer therapy by harnessing the power of gamma delta T cells. The company believes that its Gammabody™ platform has the potential to provide durable immune responses and improve patient outcomes across multiple types of cancers.
Lava Therapeutics has a diverse pipeline of Gammabody™ candidates for different types of cancers, including solid tumors and hematological malignancies. The company's lead product, LAVA-051, is in phase 1/2a clinical trials for patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). LAVA-051 targets CD1d, a molecule that is expressed on both tumor cells and antigen-presenting cells, and can activate both gamma delta T cells and natural killer T (NKT) cells.
Lava Therapeutics has received several awards and recognitions for its innovative approach to cancer therapy. In 2020, the company was named one of the Fierce 15 biotech companies by Fierce Biotech, a leading industry publication. In 2021, the company completed a successful initial public offering (IPO) on the Nasdaq stock exchange, raising $100 million to advance its clinical development.
Foundation: 2016
Headquarters: Utrecht, Utrecht, Netherlands
Website: https://www.lavatherapeutics.com/
